CRYOPORT INC. overview

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire NASHVILLE, Tenn., March 4, 2025 FY 2024 revenue of $228.4 million , in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024 NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life...

Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 PR Newswire NASHVILLE, Tenn., Feb. 18, 2025 NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close. In addition...

Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies PR Newswire NASHVILLE, Tenn., Jan. 21, 2025 New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life...

Moffitt Cancer Center and Cryoport Announce Strategic Collaboration PR Newswire TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn. , Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center , a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL , a 775-acre global innovation life sciences campus, and Cryoport, Inc....

Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA") PR Newswire NASHVILLE, Tenn., Jan. 6, 2025 All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological...

Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe PR Newswire NASHVILLE, Tenn., Nov. 12, 2024 Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced...

Cryoport Reports Third Quarter 2024 Financial Results PR Newswire NASHVILLE, Tenn., Nov. 7, 2024 Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain...

Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024 PR Newswire NASHVILLE, Tenn., Oct. 29, 2024 NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. In addition to the earnings...